Patient Travel and Reimbursements for AL Amyloidosis Study

This three-year rare disease study was being conducted at 75 study sites throughout the United States, Canada, Europe, and Australia. The study required a 13-month commitment from patients, and had a rigorous visit calendar for the first 3 months of treatment, thus the sponsor was seeking assistance with patient travel and coordination.

Please fill out the form on the right to review the case study.